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abstract
Keywords:

The presence of elevated human immunodeficiency virus (HIV) viral load within blood

Human immunodeficiency virus

and genital secretions is a critical driver of transmission events. Long-term suppression

(HIV) care cascade

of the viral load to undetectable levels through the use of antiretroviral therapy is stan-

Linkage to care

dard practice for the clinical management of HIV. Antiretroviral therapy therefore can

Seek and treat

play a key role in curbing HIV transmission. The results of a randomized clinical trial and

Treatment as prevention

several observational studies have now confirmed that antiretroviral therapy markedly
decreases the risk of HIV transmission. Mathematical models and population-based
ecologic studies suggest that further expansion of antiretroviral coverage within current guidelines can play a major role in controlling the spread of HIV. The expansion of
so-called “treatment as prevention” initiatives relies on maximal uptake of the HIV
continuum-of-care cascade to allow for the successful identification of people who are
not yet known to be HIV-infected, for engaging patients in appropriate care, and for
subsequently achieving sustained virologic suppression in patients with the use of antiretroviral therapy. Since 2010, the joint United Nations AIDS (UNAIDS) program has
called for the inclusion of antiretroviral treatment as a key pillar in the global strategy to
control the spread of HIV infection. This has now been invigorated by the release of the
World Health Organization’s 2013 Consolidated Antiretroviral Therapy Guidelines, which
recommends offering treatment to all HIV-infected individuals with CD4 cell counts
below 500/mm3, to serodiscordant couples, to individuals coinfected with tuberculosis
and hepatitis B virus, to pregnant women, and to children below the age of 5 years
(regardless of CD4 cell count in this groups).
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

The introduction of combination antiretroviral therapy (ART)
has been associated with significant improvement in human
immunodeficiency virus (HIV)-related morbidity and

mortality [1,2]. Long-term virologic suppression through the
use of ART is the primary goal of HIV therapy [3]. The potency
of modern ART regimens has increased in association with a
concomitant decrease in toxicity and simplification of the
regimens with the increased availability of once-daily dosing
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Table 1 e Ecologic studies of community viral load and treatment as prevention of new HIV infections [55].
Setting

Period

Evaluation

Taiwan

1984e2002

National HIV surveillance data
Transmission rate estimated by
an exponential model

Vancouver, British
Columbia, Canada

1996e2007

San Francisco

2004e2008

British Columbia,
Canada

1996e2009

Hlabisa sub-district,
KwaZulu-Natal,
South Africa

2004e2011

Prospective cohorts of
injection drug users
Median CVL
Cox regression model to
association with
HIV incidence
HIV/AIDS public health
surveillance for new
diagnoses and calculated
HIV incidence
Mean community viral load
Poisson models for CVL and
new HIV diagnoses
HAART coverage from a
centralized registry
HIV public health surveillance
for new diagnoses
Median CVL
Poisson models for CVL, ART
coverage, and new HIV diagnoses
Cohort of 16,667 HIV uninfected
individuals
ART coverage and HIV prevalence
within the surrounding
community assessed, and
rate of new seroconversions
captured

Outcomes

Ref

Transmission rate 0.391 new cases
/prevalent cases pre-ART
Transmission rate 0.184 new cases
/prevalent cases post-HAART
Overall decrease 53%
CVL associated with time to HIV
seroconversion (hazard ratio
3.32 per log10 increase)
After median viral load decreased
to <20,000 copies/mL, but showed
no statistical association with HIV incidence
Significant decline in mean CVL
2004e2008 (p ¼ 0.037)
Reduction in CVL associated with
decrease in new HIV
diagnoses (p ¼ 0.003)

[52]

547% increase in ART uptake
52% decrease in new HIV diagnoses
For every 100 additional individuals
on ART, new cases decreased
by factor of 0.97
For every 1 log10 drop in CVL, new cases
decreased by factor of 0.86
As ART coverage within a community
expands, risk of acquisition decreases:
for communities with 30e40% ART
penetration, risk of new infection dropped
38% compared to communities
with <10% ART uptake

[39]

[34]

[53]

[54]

ART ¼ antiretroviral therapy; CVL ¼ community viral load; HAART ¼ highly active antiretroviral therapy; HIV ¼ human immunodeficiency virus.

and fixed-dose combinations. As a result, HIV-infected individuals who are appropriately engaged in care are expected
to see an expansion of their life expectancy on the order of
four decades, which approaches the overall longevity of the
general population [4,5].
Despite these advances, challenges exist in the global
approach to controlling the HIV epidemic, which persists with
an estimated 2.5 million (range, 2.2e2.8 million) individuals
who may have newly acquired HIV in 2011 [6]. Prevention
strategies have focused initially on behavioral interventions
and condom use. Recent alternate biomedical prevention interventions have shown mixed results with no benefit in trials
involving the treatment of genital ulcerative disease (i.e.,
herpes simplex virus) [7]; mixed outcomes in the results of
trials of vaginal microbicides [8,9] and oral pre-exposure prophylaxis [10e12]; and positive benefit in male circumcision
trials [13]. Because of the incontrovertible benefit of ART to
HIV-infected individuals who meet treatment requirements,
attention has been focused on the potential secondary benefits that may be gained from expanding ART treatment programs with an associated decreased risk of transmission in
individuals accessing successful ART. As described later, the
results of a randomized clinical trial and several observational
studies have now confirmed that ART markedly decreases the
HIV transmission risk. Mathematical models and population-

based ecologic studies suggest that further expansion of antiretroviral coverage within current guidelines can play a
major role in controlling the spread of HIV. Maximizing programmatic identification of undiagnosed HIV-infected individuals and subsequent initiation of suppressive
antiretroviral therapy has been the focus of so-called “seek
and treat” or “treatment as prevention” initiatives.

2.
Biologic plausibility for “treatment as
prevention”
2.1.

Mother-to-child transmission

Vertical transmission has long been linked to the degree of
maternal viral load [14,15]. Use of suppressive combination
antiretroviral therapy during pregnancy, delivery, and
breastfeeding significantly reduces the risk of vertical transmission, even in the context of a resource-limited subSaharan setting where transmission occurred only in 1.1% of
live-born infants [16]. In the developed world, vertical transmission is uncommon. The transmission rate among HIVinfected women receiving ART in the United Kingdom and
Ireland was 0.7% in the setting of vaginal delivery or planned
caesarean section [17].
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Fig. 1 e The number of active HAART participants and the number of new HIV diagnoses per year in British Columbia,
1996e2011.

2.2.

HIV viral load and sexual transmission

In a community-based study of 15,127 individuals in Rakai,
Uganda, a relationship was clearly evident between the HIV
plasma viral load and the risk of transmission, and a multivariate analysis showed an increase of 2.45 in the seroconversion rate ratio [95% confidence interval (CI), 1.85e3.26] for
each log increase in the viral load [18]. The study further
showed no evidence of transmission for 51 individuals with
plasma viral loads below 1500 copies/mL [18]. In a multivariate
analysis in a study of male-to-female transmission among 493

heterosexual couples in Thailand, each log increment in the
HIV viral load was associated with an odds ratio (OR) of 1.81
(95% CI, 1.33e2.48) for transmission [19]. No transmission
events were documented for individuals with viral loads
below 1000 copies/mL [19]. In an analysis of 3381 serodiscordant couples [enrolled within the double-blind placebocontrolled randomized Partners in Prevention Herpes Simplex
Virus (HSV)/HIV Transmission trial of acyclovir for HIV
transmission] with 5017 person-years of follow-up in South
and East Africa [7], the HIV transmission risk was 2.24 per 100
person-years in a log-linear relationship to log(10) of plasma
viral load. Using this data, a mathematical model predicted a
50% reduction in transmission with a 0.70 log reduction in
plasma viral load [20].

2.3.
Antiretroviral therapy to reduce sexual
transmission of HIV

Fig. 2 e Rate of new HIV diagnoses by region in Canada,
1996e2008.

Use of sustained ART in the context of serodiscordant heterosexual relationships was associated with a reduced risk of
transmission soon after the introduction of combination regimens [21,22]. Recent observational data continue to show a
significant reduction in the transmission risk with the use of
ART. In the serodiscordant cohort nested within the Partners
in Prevention study, ART use was associated with a 92%
reduction in transmission from 2.24/100 person-years (95% CI,
1.84e2.72) to 0.37/100 person-years (95% CI, 0.09e2.04) [23]. A
meta-analysis evaluated 5,021 heterosexual couples and
found an overall reduction in the rate of transmission among
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couples receiving ART from 5.64/100 person-years to 0.46/100
person-years (95% CI, 0.19e1.09) (a 92% reduction in risk of
transmission) [24].
More recently, a randomized clinical trial, the HIV Prevention Trials Network 052 (HPTN 052)dwhich evaluated the
effect of early versus deferred ART on the transmission risk
among serodiscordant couplesdhas now been completed [25].
In this study, 1,763 couples (54% from Africa, 50% male HIVinfected partners) were randomized to receive immediate
ART (at a CD4 cell count of 350e500 cells/mm3) or deferred
therapy that was initiated after CD4 decline or at HIV symptom onset. There were 28 linked transmission events with
only one event occurring in the early ART group [hazard ratio
(HR), 0.04; 95% CI, 0.01e0.27], which is a 96% reduction in
transmission risk [25]. Some observational studies have not
demonstrated similar benefits [26]. However, the preponderance of evidence now supports a clear role for ART in reducing
HIV transmission.

3.
Evaluation of treatment as prevention
within British Columbia, Canada
3.1.

Mathematical models

Mathematical models of the potential impact of ART on the
incidence of HIV have been used extensively over the past
decade in various settings in the developed world and in
epidemics among men who have sex with men (MSM), and
have been used to assess the epidemic in sub-Saharan Africa [27]. These models are sensitive to the assumptions
made for treatment uptake, adherence, resistance to ART,
and transmission risk, but they serve to guide evaluation
and potential interventions of treatment as prevention
programs.
An early mathematical model was evaluated in British
Columbia to assess the effects of the potential expansion of
antiretroviral coverage among individuals who were eligible
for treatment, which was defined initially as a CD4 cell count
of <200 cells/mL [28]. In the semideterministic dynamic
transmission model, increasing ART coverage from a baseline
of 50e75% or 100% of people eligible under contemporary
provincial treatment guidelines (with an unchanged level of
adherence) was predicted to be associated with a decrease in
the annual incidence of HIV by 37% and 62%, respectively [28].
The model was updated to account for changing treatment
guidelines, and assessed the coverage for people deemed
eligible for therapy on the basis of a CD4 cell count < 350 cells/
mL [29]. Expanding coverage to 75% of people deemed eligible
for therapy may potentially avert 47% of new infections over 5
years [29]. Other models in the setting of developed world
epidemics have shown similar outcomes in some studies
[30,31], but not in other studies [32,33].

3.2.

within Vancouver’s Downtown Eastside neighborhood [34]. A
community viral load (calculated as the median measure of all
viral load measurements for individuals with a known HIV
status) was followed longitudinally (based on a total of 12,435
measures). The impact on HIV incidence was also evaluated,
while adjusting for risk behavior. The median community
viral load concentration fell below 20,000 copies/mL after 1998
(i.e., after the introduction of ART). The community viral load
remained independently associated with time to HIV seroconversion (HR, 3.32; 95% CI, 1.82e6.08), but this was no longer
statistically significant after median viral loads declined
below 20,000 copies/mL [34]. Similar decreases in the HIV
incidence have been observed in the Azimilide Post-infarct
Survival Evaluation (AIDS Linked to the Intravenous Experience cohort, ALIVE) cohort (Baltimore, MD, USA) in which the
incidence decreased by 74% for every log decrease in the
community viral load [35]. In addition, there has been no evidence of behavioral disinhibition among a cohort of injection
drug users in Vancouver where the initiation of antiretroviral
therapy was not associated with a subsequent increase in
unprotected intercourse [adjusted odds ratio (aOR), aOR 0.87;
95% CI 0.60e1.25] or multiple sexual partnerships (aOR, 0.93;
95% CI, 0.61e1.40) in a multivariate analysis [36]. This result is
in keeping with findings from ART programs in sub-Saharan
Africa [37]. However, the contrasting results showing increases in unprotected intercourse have been observed
among certain MSM populations [38].
A population-based ecologic evaluation of ART expansion
and decreasing new HIV diagnoses has been presented [39].
Antiretroviral therapy is provided free of charge to HIVinfected individuals within the Province of British Columbia,
Canada via a central Drug Treatment Program, which maintains a population-based registry of individuals receiving ART.
Between 1996 and 2012, the number of individuals receiving
therapy increased by 547% from 837 individuals to approximately 7,700 individuals. During this period, the proportion of
individuals with a viral load less than 500 copies/mL increased

Ecologic studies

The effects of ART at a community and population level have
been evaluated in British Columbia and in other settings
(Table 1). During the period of 1996e2007, the effect of ART on
HIV incidence was assessed in a cohort of injection drug users

Fig. 3 e Spectrum of engagement in care in the United
States.
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from less than 10% to 50% (p <0.0001). Between 1996 and 2012,
new diagnoses of HIV decreased overall from 702 cases to 248
cases per year (see Fig. 1). The number of HIV diagnostic tests
increased during this period, and the rates of syphilis,
gonorrhea, and chlamydia increased, which suggests no
changes in risk behavior [39]. The overall effectiveness of
current regimens has improved viral load suppression. The
proportion of individuals achieving full virologic suppression
(with a plasma viral load less than 50 copies/mL) increased
from 64.7% (in 2000) to 87.0% (in 2008) [40]. In addition, the
proportion of individuals with a resistance to more than two
drug classes has fallen from 12% of individuals in 2000 to less
than 2% of individuals currently enrolled in the program [41].
These findings stand in contrast to other jurisdictions in
Canada where new diagnosis rates of HIV are either stable or
increasing (Fig. 2) [42].

3.3.

Cost effectiveness

In the British Columbia model, cost-savings accrue over time
with averted infections. Expanding ART access from 50% to
75% of individuals meeting the 2008 treatment guideline
criteria has been predicted to result in an eventual costsavings of $900 million over 30 years [43]. In an updated
model in South Africa, expanding coverage to individuals with
CD4 cell counts of 350 cells/mm3, 500 cells/mm3, or any CD4
level would avert infections and be cost-saving; these benefits
would be diminished if patient retention in care programs
were diminished [44,45]. By contrast, in models that have
evaluated scenarios in which treatment programs do not
achieve full implementation or coverage, costs would in fact
increase [46].

3.4.

The continuum-of-care cascade

The HIV care cascade has been a seminal framework in which
to evaluate potential gaps in HIV programs [47]. The care
cascade evaluates the HIV treatment model from initial estimates of undiagnosed individuals living with HIV through the
proportion of individuals who are appropriately diagnosed,
who are engaged and retained in care, and who ultimately
achieve sustained virologic suppression. Each aspect of this
care cascade should be maximized if treatment as prevention
programs are to succeed. Gardner et al [47] evaluated the care
cascade for the United States (U.S.) as a whole, and based
estimates on reported values for each step (Fig. 3). Of the 1.2
million HIV-infected individuals in the U.S., approximately
20% were unaware of their diagnosis, and ultimately only 19%
of individuals were successfully retained and their viral load
was suppressed on ART. These estimates are remarkably
similar to the U.S. Centers for Disease Control and Prevention
(CDC) estimates obtained by using a number of U.S. national
surveillance instruments that showed 28% of all HIV-infected
individuals’ viral loads were fully suppressed on ART [48]. A
similar HIV care cascade has been generated for British
Columbia that evaluates estimated undiagnosed cases within
the province, patients engaged and retained in care, patients
adherent to medications, and patients with fully suppressed
viral loads [49]. In this model, virologic suppression was
defined as a sustained undetectable plasma viral load (i.e., less
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than 50 copies/mL during the period of 1999e2009). Only 14%
of individuals overall were believed to be undiagnosed in 2009,
compared to 47.1% in 1996. In 2009, 32.1% (range, 26.8%e
37.3%) of individuals had a fully suppressed viral load [49].

4.

Conclusions

Antiretroviral therapy can reduce individual level morbidity
and mortality for people affected by HIV, and it significantly
reduces the transmission risk, particularly among heterosexual serodiscordant couples. At a population level, the
expansion of successful ART programs translates into
decreased community burden of viremic individuals and a
concomitant decrease in the transmission of HIV and a
decreased incidence of HIV. Potential barriers may include the
impact of acute HIV infections as a cause of ongoing transmission, the efficacy of ART for prevention benefits within the
MSM communities, and the risks of concomitant behavioral
disinhibition.
At present, the overall proportion of individuals receiving
ART is low because of the high proportion of undiagnosed
individuals and because of incomplete virologic suppression
in people known to be HIV-infected. Strategies to improve
engagement at each step of the care cascade represent critical
interventions to maximize the individual and societal impact
of ART and therefore deliver on the promise of HIV treatment
as prevention. Since 2010, the joint United Nations AIDS
(UNAIDS) program has called for the inclusion of antiretroviral
treatment as a key pillar in the global strategy to control the
spread of HIV infection [50]. This has now been invigorated by
the release of the World Health Organization’s 2013 Consolidated Antiretroviral Therapy guidelines, which call for treatment to be offered to all HIV-infected individuals with CD4 cell
counts below 500/mm3, to serodiscordant couples, to individuals coinfected with tuberculosis and hepatitis B virus, to
pregnant women, and to children below the age of 5 years
(regardless of CD4 cell count in this groups) [51]. The stage is
therefore set for the global community to implement treatment as prevention as a highly cost-effective opportunity to
achieve the dual goal of halting HIV/AIDS-related morbidity
and mortality and curbing the spread of HIV.
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